1. Home
  2. AUPH vs PDX Comparison

AUPH vs PDX Comparison

Compare AUPH & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.03

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PDX

PIMCO Dynamic Income Strategy Fund of Beneficial Interest

HOLD

Current Price

$21.13

Market Cap

904.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUPH
PDX
Founded
1993
2019
Country
Canada
NY
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
904.4M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
AUPH
PDX
Price
$14.03
$21.13
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$17.25
N/A
AVG Volume (30 Days)
928.7K
134.9K
Earning Date
02-26-2026
01-01-0001
Dividend Yield
N/A
4.95%
EPS Growth
5075.00
N/A
EPS
2.07
N/A
Revenue
$283,055,000.00
N/A
Revenue This Year
$17.35
N/A
Revenue Next Year
$15.66
N/A
P/E Ratio
$6.79
N/A
Revenue Growth
20.38
N/A
52 Week Low
$6.83
$18.47
52 Week High
$16.54
$25.25

Technical Indicators

Market Signals
Indicator
AUPH
PDX
Relative Strength Index (RSI) 43.89 68.59
Support Level $13.52 $20.93
Resistance Level $15.23 $22.15
Average True Range (ATR) 0.46 0.37
MACD -0.02 0.06
Stochastic Oscillator 12.59 92.32

Price Performance

Historical Comparison
AUPH
PDX

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.

Share on Social Networks: